SCART and Hypofractionation Rapidly Reduced a Bulky Sternal Metastasis in Metastatic NSCLC
A bulky metastatic lesion can change the treatment sequence in advanced lung cancer long before systemic therapy ever starts. In this case report, a 67-year-old man with metastatic squamous non-small cell lung cancer arrived with a rapidly enlarging sternal metastasis measuring 100 mm at its widest point, severe pain, dyspnea, and difficulty eating. His functional reserve was already strained: Karnofsky performance status was 70, and he also had marked anemia, hypoalbuminemia, and a high nutritional risk burden. Those baseline features mattered because they limited immediate systemic treatment and made fast local control more than a radiographic goal; it was a way to stabilize the patient enough to pursue the next line of care.
The case centers on an unusual but clinically logical sequence: stereotactic centralized ablative radiation therapy for the bulky sternal lesion, followed by hypofractionated radiotherapy. The sternal metastasis received 36 Gy in 3 fractions, while the primary lung tumor was treated concurrently with HFRT at 30 Gy in 10 fractions. After that initial ablative phase, the patient continued with HFRT to the sternal lesion at 45 Gy in 15 fractions. The rationale is straightforward at the bedside. High-dose focal radiation can create a rapid cytotoxic hit in the center of a large mass, while the surrounding dose gradient helps protect adjacent normal tissue. In a patient who cannot yet receive systemic therapy, local debulking can restore swallowing, breathing, and pain control quickly enough to reopen other treatment options.
The response was fast. Three weeks after radiotherapy, the sternal metastasis had shrunk from 100 mm to 46 mm, and the primary lung tumor had decreased from 67 mm to 40 mm. Symptom relief tracked the imaging response: pain, dyspnea, and eating difficulty improved in parallel with the reduction in tumor burden. This is the kind of turnaround that radiation oncologists look for when a lesion is causing immediate mechanical and inflammatory compromise. Tumor shrinkage at this pace can reduce chest wall mass effect, ease respiratory discomfort, and improve oral intake before the patient slips further into catabolic decline.
Functional Reserve Improved Enough to Open the Door to Systemic Treatment
The clinical consequence extended beyond the scan. Once the local tumor burden fell and symptoms eased, the patient was able to move on to systemic therapy with paclitaxel, carboplatin, and penpulimab. For patients with advanced disease, that transition can be the difference between a treatment plan that stalls and one that resumes disease control across both visible and microscopic tumor sites. In this setting, radiation did not replace systemic therapy; it made systemic therapy possible by reducing the immediate burden that was driving poor intake, anemia-related weakness, and overall frailty.
Nutritional support ran alongside the radiation course, and in a patient with hypoalbuminemia and high nutritional risk, that support was not ancillary. Large symptomatic tumors can accelerate weight loss and protein depletion through reduced intake and ongoing inflammatory stress. When a lesion is painful enough to impair eating and breathing, local therapy and nutrition are linked biologically: as tumor burden falls, appetite and intake can recover, which in turn supports tolerance of subsequent treatment. The case therefore reflects a practical sequence in advanced oncology care—local control first, then systemic treatment once the body can tolerate it.
Safety also matters here. No grade 3 or higher acute radiation-related toxicity was observed during follow-up. For a large chest wall and sternal target, that absence is clinically relevant because dose intensification in bulky disease raises concern for damage to nearby structures and for early intolerance in a patient who is already nutritionally and functionally vulnerable. The report does not claim that this approach is universally safe; it shows feasibility in one patient under close multidisciplinary management.
Why Centralized Ablative Dosing May Help in Bulky Disease
The appeal of SCART in bulky metastases lies in dose distribution. Instead of trying to sterilize an entire large mass with the same uniform intensity, centralized ablative delivery concentrates the highest dose within the tumor core, where hypoxic and clonogenic cells often persist, while limiting surrounding normal tissue exposure. That strategy may be especially relevant in symptomatic bulky disease, where the immediate objective is not only local control but also fast decompression of a painful, function-limiting mass.
In this case, the large sternal metastasis was the dominant clinical problem. The lesion was rapidly enlarging, symptomatic, and physically compromising daily function. A one-size-fits-all palliative regimen might have provided slower shrinkage or less dramatic debulking. The combined SCART plus HFRT sequence was used to pursue a more aggressive local response without waiting for systemic therapy to take hold. The radiographic reduction at three weeks suggests that this sequencing can produce meaningful short-term tumor regression in carefully selected patients.
A Single-Patient Signal, Not a Practice-Defining Trial
The evidentiary weight here remains narrow. This is a case report, and a single patient cannot define comparative efficacy, ideal fractionation, or long-term durability. The follow-up also does not answer whether the same approach would perform similarly across other histologies, metastatic sites, or patients with different degrees of marrow suppression, nutritional compromise, or chest wall involvement. What this case does show is a coherent clinical pathway: targeted radiation can quickly relieve the burden of a bulky metastasis, improve symptoms, and create the conditions for later systemic therapy.
A second limitation is the lack of a control condition. The tumor shrinkage and symptom improvement occurred after SCART, HFRT, and nutritional support were delivered together, so the contribution of each element cannot be separated. Even so, the sequence is biologically plausible and clinically useful. Radiation reduced the tumor load, symptom relief improved intake and function, and the patient then became eligible for paclitaxel, carboplatin, and penpulimab. For radiation oncologists facing a patient with a large symptomatic metastasis and little immediate room for systemic therapy, that sequence offers a concrete model for bedside decision-making rather than a generalized claim.
The report ends with a practical message: in bulky symptomatic metastatic non-small cell lung cancer, centralized ablative radiation followed by hypofractionation can produce rapid local tumor debulking without severe acute toxicity in at least one patient. The unresolved question is how often this approach can be reproduced, which patients are most likely to benefit, and how best to integrate it with systemic treatment and nutritional rehabilitation in routine practice.